GlassScriptPhysician profile
Kishore Sriram
NPI 1710179908
$1,650.73
in general payments reported to CMS, 2019-2025
23 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $94.75 · 2021: $124 · 2022: $435 · 2023: $108 · 2024: $96.83 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $383.01 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $194.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $175.59 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $157.84 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $97.61 | 2019-2023 | Spravato, Invega, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.50 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $66.27 | 2025 | Cobenfy |
| Indivior INC. | $56.98 | 2022 | |
| Vanda Pharmaceuticals INC. | $54.70 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $50.98 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.55 | 2019-2022 | |
| Axsome Therapeutics, INC. | $41.01 | 2022-2024 | Auvelity |
| Lundbeck LLC | $40.07 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.90 | 2022-2023 | Uzedy |
| Biogen, INC. | $28.67 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $28.22 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.27 | 2024 | Qelbree |
| Corcept Therapeutics | $18.94 | 2025 | Korlym |
| Dexcom, INC. | $18.18 | 2024 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $17.73 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.53 | 2019 | |
| Shire North American Group INC | $16.18 | 2019 | |
| Tris Pharma INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishore Sriram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.